Key Takeaways
- H1 on track, H2 acceleration promised: Revenue and PAT growth in H1 FY26 are in line with the full-year guidance of at least 50% top-line and 100% PAT growth, with management expecting an even stronger second half.
- Own-product launches are lifting margins: Regulated market EBITDA hit 44% in Q2, driven by a higher share of own products launched during the quarter, a mix shift management says is sustainable.
- Emerging markets are the drag: Revenue grew only 4% YoY in H1 as dollar appreciation caused buyers to hold back and new registrations stalled on import permit delays and geopolitics.
- A 25-30% CAGR target is on the table, not yet a commitment: Management sees at least 30% CAGR sustainable growth over the next 3-5 years as "very much visible," but the Chairman explicitly framed it as a target, not guidance.
- What to watch next quarter: Whether the 6-8 planned ANDA launches in H2 convert to revenue, whether emerging market growth returns to double digits, and whether the promised H2 margin holds at H1 levels.
Regulated Markets: The Margin Engine
- Own-product mix is the story: New product launches every quarter for the next four to five quarters are increasing the margin profile. Own products operate under a profit-share model with licensing fees and COGS reimbursement; as the basket grows, profit share becomes the major sustainable contributor.
- US combined entity delivers 40-42% EBITDA: Havix should not be viewed in isolation; it is integral with Senores Inc., the wholly-owned US subsidiary holding marketing intangibles and IP, which on a consolidated basis delivers that margin.
- CGT exposure is contained: CGT-designated products are generics with relatively controlled price erosion risk. Revenue exposure is 20-25% and not expected to substantially increase or decrease. The company has not encountered any of the feared risks (competition after exclusivity, regulator pressure) so far, partly because these are not large opportunities that attract many players post-exclusivity.
- CDMO-CMO provides a derisking layer: The strong CDMO-CMO portfolio, US government supplies, and controlled substances serve as a derisking strategy alongside the CGT business. The segment is expected to grow at about 30% CAGR over the next three to five years.
- H2 regulated market target: Internal target of top-line in excess of INR400 crores, with own products slightly 5-10% higher than CDMO-CMO in the split.
Swapnil Shah: "So far -- all your stated risks are correct. But so far, have we encountered any of those stated risks? The answer is no."
Emerging Markets: Waiting on the Turn
- Two headwinds stalled growth: Dollar appreciation is causing buyers to hold back and wait for their currencies to stabilize. Simultaneously, new registrations have not yet converted to commercial orders due to import permit delays and geopolitical issues.
- The business has turned cashflow positive despite the slow top-line, and management expects double-digit growth from Q1 FY26-FY27, with the Chairman adding that this year itself will see double-digit growth on the emerging market side.
- Margin trajectory is a multi-year climb: Current 6-7% EBITDA margin should reach early double digits by the end of this year, with a mid-teens target over a 2-3 year horizon. Visibility is based on order visibility for the remaining quarter.
- Working capital will stretch: The working capital cycle could go to 90-100 days as emerging market business picks up in the second half.
Swapnil Shah: "there are two issues that are driving, or maybe I would say not giving us, the kind of growth momentum that we need in the emerging market. One is the dollar appreciation across, right? So, people are kind of holding back and wanting their currency to stabilize."
Portfolio Build-Out: Launches, Facilities & Backward Integration
- 8 new products launched in Q2, including some from the recently acquired portfolio; initial launches were extremely successful. The owned portfolio now stands at 81 products, with the CDMO-CMO segment at ~32 products.
- 6-8 ANDA launches planned for H2, including the acquired portfolio, with a further 8-10 ANDA products targeted for H1 FY27.
- US capacity expansion underway: A third manufacturing line at the US facility is expected operational in Q3 FY26, with a fourth line towards the end of FY26, taking total capacity from 120 crore units to approximately 200 crore units.
- Sterile manufacturing facility planned: A US sterile facility, including biologic CDMO-CMO capability, is planned for Q2-Q3 FY27. Revenue or margin guidance was called premature.
- API backward integration is a margin lever: The first API facility is projected to get US FDA approval in Q2 FY26-FY27, with targeted revenue of INR50-100 crores in the next year, largely driven by internal pipeline for supply chain protection. For single-source products, the company expects to have its own product from its own facility in the next year or two. The make-or-buy decision will be based on cost, integrating where margin expansion is possible.
- Semaglutide filings underway: Tablets dossiers have been filed in close to 12-14 ROW markets, an injectable dossier is also being filed, and a PFS line has been installed in-house. The opportunity could be sizable, but management cannot size it precisely due to a lack of IMS/IQVIA data in emerging markets.
Swapnil Shah: "How large? It's difficult to state because in this emerging market, there are no IMS data or IQVIA data available where we could extrapolate and say we will gain 5%, 10% market share, and this will be the opportunity number for us."
Acquisitions & Turnarounds
- Ratnatris turnaround is a proof point: Acquired in 2022 with INR55-56 crore revenue and cash losses, revenue has grown approximately 3x to INR150-odd crore in three years. Registrations grew 6x from 48 to 394, and per-unit realization improved from INR1.2 to INR1.8-INR1.9. Margins are in the lower teens this year, with higher teens expected next year.
- Zoraya Pharmaceuticals is a new formation, not an acquisition: Senores acquired a 51% interest in Zoraya Pharmaceuticals LLC, a newly formed US joint venture. The remaining 49% is held by someone with decades of US marketing experience and existing infrastructure. Some acquired ANDAs will be launched under the Zoraya platform. There was no acquisition cost; whatever is contributed will be the cost.
- Havix margins are now at sustainable levels: Prior years' margins reflected capacity building at a greenfield unit that started commercial transactions in 2019 and was then hit by COVID. Current and next year's margins are the actual sustainable levels going forward.
Swapnil Shah: "So, revenue in three years has grown -- will grow about 3x. The registration that they had was about 48; we are at 394 today. So, the number of registrations has gone up by 6 times."
India Branded Generics: The Domestic Build
- PAN-India coverage targeted by end of FY26, with the business on track to reach approximately INR50 crore revenue in FY26.
- Next year's target is INR100 crore, with more divisions to be launched. Current gross margins are around 30%, with EBITDA at 18-20%; as more products are added and PAN-India expansion happens, margins and gross profit are likely to scale up further.
Margins & Cash Flow
- Gross margins are sustainable at current levels, and may improve depending on particular quarter launches. The sustainable gross margin range is 60-65%, though exact working once API kicks in is premature.
- Sustainable EBITDA of 28-30% is targeted from next year onwards, with PAT as a percentage improving by a couple of hundred basis points.
- H2 margin guidance is in a similar range to what was achieved in H1.
- Cash flow conversion improved considerably from the previous year; despite 66% H1 growth, capital efficiency improved. As the business scales further, the cash flow from operations to EBITDA ratio will increase further.
- Employee expenses jumped due to an increment done in August with arrears from April (retrospective), a salary revision for Directors, and key person additions in the US business.
Sanjay Majmudar: "I think a sustainable EBITDA of 28% to 30% is what we are looking at from next year onwards. And therefore, on a like-to-like basis, since we don't have too much of a debt burden, you can work out the PAT, but PAT as a percentage will improve by a couple of hundred BPS. That's what we are looking at."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 top-line growth | At least 50% growth over FY25 | FY26 full year |
| FY26 PAT growth | 100% growth over FY25 | FY26 full year |
| US facility capacity expansion | Third line operational; fourth line by end FY26; total capacity ~200 cr units | Q3 FY26 and end FY26 |
| ANDA launches | 6-8 launches in H2 FY26; 8-10 in H1 FY27 | H2 FY26 and H1 FY27 |
| India branded generics revenue | ~INR50 cr in FY26; ~INR100 cr next year | FY26 and FY27 |
| PAN-India branded generics coverage | Achieve full coverage | End of FY26 |
| API facility US FDA approval | First facility approval; second facility to manufacture key products post-approval | Q2 FY26-FY27 |
| API facility revenue | INR50-100 crores, largely from internal pipeline | FY27 |
| Emerging market EBITDA margin | Early double digits by end of this year; mid-teens over 2-3 years | End FY26 and FY28-FY29 |
| Sustainable EBITDA margin | 28-30% | From FY27 onwards |
| Sustainable gross margin | 60-65% | Ongoing |
| CDMO-CMO growth | ~30% CAGR | Next 3-5 years |
| Ratnatris margin trajectory | Lower teens this year, higher teens next year | FY26 and FY27 |
| US sterile manufacturing facility | Construction planned | Q2-Q3 FY27 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated income | ₹162 cr, +61% YoY and +17% QoQ |
| EBITDA | ~₹50 cr, +113% YoY |
| EBITDA margin | 31%, +750 bps YoY and +580 bps QoQ |
| Profit after tax | ₹30 cr, +131% YoY |
| Regulated markets revenue | ₹107 cr, +87% YoY and +19% QoQ |
| Regulated markets EBITDA margin | 44% |
| Emerging markets revenue | ₹32 cr, +9% QoQ |
| Emerging markets EBITDA margin | 6.6% |
| Domestic branded generic revenue | ₹12 cr, >10x YoY |
| Operating cash flow (H1 FY26) | ~₹31 cr, >3x ₹9 cr in H1 FY25 |
| Cash flow from operations to EBITDA (Q2) | 40% |
| Owned product portfolio | 81 products as of Q2 FY26 |
| New products launched in Q2 | 8 products |
| Emerging markets registered products | 394 as of Sep 30, 2025, with 824 under registration |
| CDMO-CMO visible business for FY26 | $12 mn |
| Out-licensing income | ₹0.12 cr |